Scarica l'app Stockscreener
205.55
0.50%
1.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Astrazeneca Plc Borsa (AZN) Ultime notizie
Cookson Peirce & Co. Inc. Invests $1.05 Million in AstraZeneca PLC $AZN - MarketBeat
Advisors Asset Management Inc. Acquires 8,453 Shares of AstraZeneca PLC $AZN - MarketBeat
Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectory - Yahoo Finance
Shore Capital lowers AstraZeneca to 'hold' - Sharecast.com
Published on: 2026-02-13 16:14:39 - mfd.ru
AstraZeneca's (AZN) Breztri Aerosphere Shows Promising Results i - GuruFocus
AstraZeneca's BREZTRI Shows Significant Asthma Improvement in Phase III Trials - Intellectia AI
Caprock Group LLC Takes $3.10 Million Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca Announces BrePREMIUM Trial Results - Intellectia AI
AstraZeneca Says Breztri Improves Lung Function, Reduces Attacks in Phase 3 Asthma Trials - marketscreener.com
AstraZeneca Earnings: Strong Finish to Year, and Busy Schedule of Data Readouts Ahead - Morningstar Canada
AstraZeneca PLC (LON:AZN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review (UPDATED) - Benzinga
AstraZeneca's Portfolio and Pipeline Support Solid Long-Term Growth - Morningstar
6,649 Shares in AstraZeneca PLC $AZN Acquired by Westover Capital Advisors LLC - MarketBeat
Here’s What Lifted AstraZeneca PLC (AZN) in Q4 - Insider Monkey
Madison Asset Management LLC Trims Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
Big Deal, Bigger Doubts: CSPC Slides After $18.5B Pact With AstraZeneca - Benzinga
Kangtai Drops Plan for China Vaccine JV With AstraZeneca - Citeline News & Insights
AstraZeneca awards $3.4 million to US nonprofits to expand healthcare access - MSN
AstraZeneca PLC (AZN) Q4 2025 Earnings Call Highlights: Strong R - GuruFocus
AstraZeneca (LON:AZN) Hits New 52-Week HighHere's What Happened - MarketBeat
China charges former AstraZeneca regional head Leon Wang - marketscreener.com
AstraZeneca (AZN) Faces Legal Challenges in China - GuruFocus
Former AstraZeneca regional head charged in China (AZN:NYSE) - Seeking Alpha
AstraZeneca And Daiichi Sankyo Stack The Odds For Datroway’s Lung Cancer Bets - Citeline News & Insights
How AstraZeneca shot for the moon — and hit - Financial Times
China charges former AstraZeneca executive Leon Wang - marketscreener.com
Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill - BioPharma Dive
AstraZeneca's ex-chief in China formally charged with insurance fraud - The Edge Malaysia
Chinese Authorities Charge AstraZeneca's Ex-China Business Head - marketscreener.com
Citi maintains 'buy' on AstraZeneca with £170 target, cites sector-best pipeline - Yahoo Finance UK
AstraZeneca PLC (NYSE:AZN) Q4 2025 Earnings Call Transcript - Insider Monkey
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US - marketscreener.com
$3.4M for 47 local groups tackling care gaps, nutrition and lung disease - Stock Titan
China charges former AstraZeneca executive - Financial Times
AstraZeneca PLC (NYSE:AZN) Q4 2025 earnings call transcript - MSN
What's Driving the Market Sentiment Around AstraZeneca PLC? - Benzinga
AstraZeneca PLC (NASDAQ:AZN) Sees Significant Drop in Short Interest - MarketBeat
AstraZeneca PLC $AZN Holdings Boosted by ABC Arbitrage SA - MarketBeat
AstraZeneca to advance in-licensed oral GLP-1RA to pivotal trials - Clinical Trials Arena
Astrazeneca re-doses $80bn annual sales goal - marketscreener.com
AstraZeneca (AZN) Projects Moderate Revenue Growth by FY26 - GuruFocus
AstraZeneca - Britannica
AstraZeneca stock hits all-time high at 194.18 USD By Investing.com - Investing.com Nigeria
AstraZeneca Earnings Call Highlights Growth And Pipeline - TipRanks
AstraZeneca Q4 Earnings Call Highlights - Yahoo Finance
AstraZeneca: Q4 Earnings AnalysisTicks The Boxes, Upgrading To Buy (AZN) - Seeking Alpha
AstraZeneca Q4 and FY 2025 slides: 8% revenue growth, strategic investments for 2030 By Investing.com - Investing.com South Africa
AstraZeneca's GLP-1 pill succeeds in two mid-stage trials - TechTarget
AstraZeneca Unit Settles Soliris Feud With Samsung, Amgen - Law360
AstraZeneca PLC (NASDAQ:AZN) Announces Dividend of 1.60 - MarketBeat
AstraZeneca Keeps Its Growth Engine Moving Amid Rising Costs - Kalkine Media
Market Voices: Paramount-WBD bid, Holtec IPO, AstraZeneca - Seeking Alpha
Why Is AstraZeneca Stock Gaining Tuesday?AstraZeneca (NYSE:AZN) - Benzinga
Relaxin unrest after Astrazeneca phase II HF bid joins failures - BioWorld MedTech
AstraZeneca (AZN) Surpasses Q4 Earnings Expectations, Driven by Oncology Growth - GuruFocus
Jim Cramer on AstraZeneca: “We want every drug stock” - MSN
Oakmark International Strategy Updates Portfolio, Adds AstraZene - GuruFocus
AstraZeneca bets on continued oncology demand for 2026 growth - Pharmaceutical Technology
Jim Cramer on AstraZeneca: "We Want Every Drug Stock" - Finviz
Jim Cramer on AstraZeneca: “We Want Every Drug Stock” - Insider Monkey
Sustained By Cancer Success, AstraZeneca Is Still Sizing Up Obesity Opportunity - Citeline News & Insights
AstraZeneca profits boosted by strong cancer drug sales - Investors' Chronicle
The $80 Billion Ambition: An In-Depth Analysis of AstraZeneca (AZN) in 2026 - FinancialContent
1.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):